<DOC>
	<DOCNO>NCT00180128</DOCNO>
	<brief_summary>In AIDA 2000 therapy acute promyelocytic leukemia ( APL ) give risk-adapted manner . Risk factor age white-blood-cell ( WBC ) -count diagnosis . Induction therapy do ATRA idarubicin follow postremission therapy daunorubicin mitoxantrone age adapt dosage . Patients high WBC additionally treat cytarabine . Finally two year period maintenance therapy 6-mercaptopurine , methotrexate ATRA perform .</brief_summary>
	<brief_title>AIDA2000 - Risk-Adapted Therapy Patients With Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>In AIDA 2000 therapy acute promyelocytic leukemia ( APL ) give risk-adapted manner . Risk factor age white-blood-cell ( WBC ) -count diagnosis . Induction therapy do ATRA idarubicin follow postremission therapy daunorubicin mitoxantrone age adapt dosage . Patients high WBC additionally treat cytarabine . Finally two year period maintenance therapy 6-mercaptopurine , methotrexate ATRA perform .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>acute promyelocytic leukemia confirm detection ( 15 ; 17 ) and/or PML/RARa contraindication chemotherapy write informed consent severe comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>acute promyelocytic leukemia</keyword>
	<keyword>risk adapt therapy</keyword>
</DOC>